Daewoong Pharmaceutical Confirms N-blo Improves Fatty Liver Indices in Type 2 Diabetes Patients
"Evidence Secured for Preventing Liver Metabolic Disorders and Complications"
Daewoong Pharmaceutical has confirmed the potential of its novel diabetes drug, N-blo (ingredient: inavogliflozin), to improve fatty liver in patients with type 2 diabetes.
On July 9, Daewoong Pharmaceutical announced that the results of a study confirming the potential of N-blo, an SGLT-2 inhibitor-class diabetes drug, to improve hepatic steatosis have been published in the SCI-level international journal "Diabetes, Obesity and Metabolism (DOM)." This study evaluated the impact of N-blo on "metabolic dysfunction-associated steatotic liver disease (MASLD)," a condition commonly associated with diabetes patients.
The research team integrated data from three clinical trials conducted for the approval of N-blo and analyzed the therapeutic effect over 24 weeks in 587 patients with type 2 diabetes. Fatty liver indices were measured using the Hepatic Steatosis Index (HSI) and Framingham Steatosis Index (FSI).
The analysis showed that a higher proportion of patients in the N-blo treatment group experienced a reduction in fatty liver indices compared to the placebo group. Among the 75 study participants, the number of patients with fatty liver based on HSI criteria decreased from 36 (48.0%) to 12 (16.0%), meaning approximately 67% of patients with pre-existing fatty liver recovered to normal levels. According to the FSI metric, the number of patients in the at-risk group decreased from 31 (41.3%) to 12 (16.0%), indicating that about 61% of at-risk patients improved to the normal range.
When compared to dapagliflozin, another drug of the same class, the N-blo treatment group achieved a greater improvement in fatty liver indices. The change in HSI for the N-blo group was -4.51, greater than the dapagliflozin group’s -3.49.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Park Hyungcheol, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "These study results demonstrate that N-blo can provide additional therapeutic benefits beyond glycemic control by improving fatty liver indices. Given that MASLD is present in more than 65% of patients with type 2 diabetes, these findings support the potential for N-blo to expand its therapeutic value in real-world clinical settings."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.